Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 16, 2016 - Issue 9
Submit an article Journal homepage
4,811
Views
11
CrossRef citations to date
0
Altmetric
Editorial

Pembrolizumab: the value of PDL1 biomarker in head and neck cancer

Raffaele AddeoU.O. Oncologia, ASL NA2 NORD, Department of Oncology, Frattamaggiore, ItalyCorrespondence[email protected]
View further author information
,
Michele CaragliaDepartment of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, ItalyView further author information
&
Giada IulianoMerck Sharp Dohme, Department of Oncology, Milan, ItalyView further author information
Pages 1075-1078 | Received 21 May 2016, Accepted 07 Jul 2016, Published online: 21 Jul 2016

References

  • Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007;4:156–171. doi:10.1038/ncponc0750.
  • Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–1127. doi:10.1056/NEJMoa0802656
  • Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1: PD-L1pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 73(6): 1733–1741. 2013. 10.1158/0008-5472.CAN-12-2384.
  • Méry B, Guy JB, Espenel S, et al. Targeting head and neck tumoral stem cells: from biological aspects to therapeutic perspectives. World J Stem Cells. 2016;8(1):13–21. DOI:10.4252/wjsc.v8.i1.13.
  • Postow MA, Harding J, Wolchok JD. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J. 2012 Mar-Apr;18(2):153–159. doi:10.1097/PPO.0b013e3182610e38.
  • Hatam LJ, Devoti JA, Rosenthal DW, et al. Immune suppression in premalignant respiratory papillomas: enriched functional CD4þFoxp3þ regulatory T cells and PD-1/PDL1/L2 expression. Clin Cancer Res. 2012;18:1925–1935. doi:10.1158/1078-0432.CCR-11-2941.
  • Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891–1901. doi:10.1001/jama.2011.1592.
  • Schoenfeld JD. Immunity in head and neck cancer. Cancer Immunol Res. 2015;3(1):12–17. doi:10.1158/2326-6066.CIR-14-0205.
  • Lin YM, Sung WW, Hsieh MJ, et al. High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. PLoS One. 2015 12; 10(11): e0142656. 10.1371/journal.pone.0142656.
  • Lin YM, Sung WW, Hsieh MJ, et al. High PD-L1 expression correlates with metastatic and poor prognosis in oral squamous cell carcinoma. PLoS One. 2015 Nov 12;10(11):e0142656.
  • Saloura V, Zuo Z, Koeppen H, et al. Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck cancer. J Clin Oncology, 2014 ASCO Annu Meet Abstr. 2014;32(15_suppl (May 20 Supplement)):6009.
  • Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028. doi:10.1056/NEJMoa1501824.
  • Seiwert T, Burtness B, Weiss J, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. J Clin Oncology. 2014; 32(15_suppl (May 20 Supplement)):6011. ASCO Annu Meet Abstr.
  • Ferris RL, Blumenschein GR, Fayette J, et al. Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. J Clin Oncol. 2016;34(suppl; abstr 6009).
  • Ferris RL Immunology and. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015;33(29):3293–3304. doi:10.1200/JCO.2015.61.1509.
  • Cho YA, Yoon HJ, Lee JI, et al. Relationship between the expressions of pd-l1 and tumor-infiltrating lymphocytes in oral squamouscell carcinoma. Oral Oncol. 2011;47:1148–1153. doi:10.1016/j.oraloncology.2011.08.007.
  • Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520. doi:10.1056/NEJMoa1500596
  • Schmid P, Hegde PS, Zou W, et al. Association of PD-L2 expression in human tumors with atezolizumab activity. J Clin Oncol. 2016; 34(suppl; abstr 11506)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.